Research Team Led by Professor Kim Nayoung at Seoul National University Bundang Hospital
Significant Improvement in Survival Rate for Men Treated with Immune Checkpoint Inhibitors
No Significant Difference Observed in Female Patients

A study has found that the effectiveness of immune checkpoint inhibitors in treating gastric cancer varies depending on the patient's sex. While male gastric cancer patients experienced a significant increase in survival time, no clear difference was observed in female patients.


On January 29, Seoul National University Bundang Hospital announced that a research team led by Professor Kim Nayoung from the Department of Gastroenterology analyzed 468 gastric cancer patients who underwent PD-L1 immunohistochemistry at the hospital between 2018 and 2024, confirming these findings. The results were published online in the latest issue of the Korean Cancer Association’s international journal, Cancer Research and Treatment.

Comparison of the immune microenvironment in gastric cancer between men and women. Women have a complex immune environment, limiting the response to immune checkpoint inhibitors. Seoul National University Bundang Hospital

Comparison of the immune microenvironment in gastric cancer between men and women. Women have a complex immune environment, limiting the response to immune checkpoint inhibitors. Seoul National University Bundang Hospital

View original image

Immune checkpoint inhibitors are immuno-oncology drugs that block the signaling pathway (immune checkpoint) cancer cells use to disguise themselves from immune cells. In a normal immune response, T lymphocytes (T cells) attack and eliminate tumor cells. However, cancer cells express PD-L1 to evade this response.


Immune checkpoint inhibitors work by blocking the binding between the PD-L1 protein and the PD-1 receptor on immune cells, thereby enabling T lymphocytes to actively kill cancer cells. Unlike cytotoxic chemotherapy, which chemically destroys cancer cells, or targeted therapies that focus on specific mutations or receptors, immune checkpoint inhibitors utilize the body’s own T lymphocytes, making their mechanism of action distinct.


The research team compared PD-L1 expression and the outcomes of immune checkpoint inhibitor treatment by sex. Among male patients, the median survival time for the PD-L1 positive group who received immune checkpoint inhibitors was 1,314 days, longer than the 950 days observed in the non-treatment group. In contrast, among female patients, there was no significant difference between the treatment group (897 days) and the non-treatment group (890 days).


The researchers suggested that pathological and molecular biological sex differences in gastric cancer may have influenced these differences in treatment response. In men, PD-L1 positive gastric cancer tended to be associated with Epstein-Barr virus (EBV) or to occur in the lower part of the stomach. Both factors are linked to active immune responses, which may have contributed positively to the effectiveness of immune checkpoint inhibitor therapy.


In women, there was no significant association between PD-L1 positive gastric cancer and either EBV or antral cancer, and multiple immune suppression mechanisms appeared to be at play. Therefore, the researchers estimated that PD-L1/PD-1 inhibitors alone have limited effectiveness in female patients.



Professor Kim stated, "Since there are clear differences in the immune systems of men and women, a more detailed approach that considers 'sex-based immunology' is necessary when treating gastric cancer with immune checkpoint inhibitors. It is important to establish optimized immunotherapy guidelines for both men and women through future large-scale data studies."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing